
Prior Authorization DRUG Guidelines

CALCIPOTRIOL (calcipotriene 0.005% cream) Effective

Date: 8/18/2020

Date Developed: 8/18/2020 by Dr. H. Taekman

Last Approval Date: 8/18/2020, 8/3/21, 2/1/22, 1/31/23

Synthetic vitamin D2 analog which regulates skin cell production and proliferation. Binds to vitamin D receptors and inhibits keratinocyte proliferation and enhances keratinocyte differentiation

Pre-Authorization Criteria:

Treatment of plaque psoriasis of the body (cream, ointment) or of the scalp (solution) in adults; treatment of plaque psoriasis of the body or of the scalp in children ≥ 12 years of age, adolescents, and adults (foam). An effective treatment when used with topical steroids. Considered first-line treatment options in pediatric patients (particularly to minimize corticosteroid exposure)

Application:

Cream, foam, ointment: Apply to affected skin twice daily; rub in gently and completely. Wash hands thoroughly after use.

Dosage Forms:

Cream, External:

0.005% (60 g, 120 g) [contains cetearyl alcohol, disodium edta]

Generic: 0.005% (60 g, 120 g)

Solution, External:

Generic: 0.005% (60 mL)

References:

1. Feldman SR, Matheson R, Bruce S, et al. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials [published correction appears in Am J Clin Dermatol. 2012;13(6):422]. Am J Clin Dermatol. 2012;13(4):261-71. doi: 10.2165/11630710-000000000-00000.
2. Hsu S, Papp KA, Lebwohl MG, et al, "Consensus Guidelines for the Management of Plaque Psoriasis," Arch Dermatol, 2012, 148(1):95-102.
3. Schachner L, Hansen R, eds. Pediatric Dermatology. 4th ed. Philadelphia, PA: Mosby Elsevier; 2011
4. Zeichner JA, Lebwohl MG, Menter A, et al, "Optimizing Topical Therapies for Treating Psoriasis: A Consensus Conference," Cutis. 2010;86(3 Suppl):5-31.
5. UpToDate: calcipotriene

Revision History:

Date Developed: 8/18/2020 by Howard Taekman, MD

Date Approved by P&T Committee: August 18, 2020

Date Reviewed/ Updated: 8/3/21 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 8/3/21

Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/1/22

Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/31/23

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
8/18/20	NEW	Howard Taekman, MD	NEW
8/3/21	Yes	Howard Taekman, MD; Robert Sterling, MD	Updated preauthorization criteria added dosage and boxed warning sections. Added references.
2/1/22	No	Howard Taekman, MD; Robert Sterling, MD	Annual review
1/31/23	No	Howard Taekman, MD; Robert Sterling, MD	Annual review